health
Claims study estimates 0.43% 45-day serious-event risk after mifepristone use
A medRxiv preprint analysing 2017–2023 claims data reports that 0.43% of mifepristone uses in its medication-abortion cohort were followed by a serious adverse event within 45 days. The retrospective study classified outcomes using claims-based criteria aligned with FDA seriousness criteria.